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Abstract 
In randomised trials, bivalirudin has been associated with higher rates of acute stent thrombosis (AST) 
compared to unfractionated heparin (UFH), without mechanistic explanation.  Furthermore, data are 
discrepant regards the antiplatelet effects of bivalirudin.  This prespecified study, part of a larger HEAT-
PPCI Platelet Substudy, aimed to compare the antiplatelet and antithrombotic effects of bivalirudin and 
UFH using short thrombelastography (s-TEG), an ex vivo whole blood platelet function assay.   In HEAT-
PPCI, patients were randomised to receive UFH or bivalirudin before angiography.  Assay with s-TEG was 
performed in 184 patients (10.2%) at end of procedure (EOP) and repeated at 24 hours.  In addition to 
adenosine diphosphate- (ADP) and arachidonic acid- (AA) mediated platelet aggregation, thrombin-
mediated clotting (TMC) was assessed using kaolin with and without heparinase.  There were no significant 
differences between UFH and bivalirudin in ADP- and AA-mediated platelet aggregation at EOP or 24 
hours.  Whilst UFH obliterated TMC at EOP, bivalirudin prolonged R time (19.7 min [15.9 – 25.4] vs. 8.4 min 
[7.5 - 10]; P < 0.0001), K time (2.4 min [1.9 - 3.4] vs. 2.2 min [1.8 - 2.7]; P = 0.007) and significantly 
increased maximum clot strength (MA 62.7 mm [58.7 - 67.4] vs. 58.6 [55 - 63]; P = 0.0005), compared to 
control.  In conclusion, there were no significant differences in the antiplatelet effects of UFH and 
bivalirudin.  However, whilst UFH obliterated TMC, bivalirudin prolonged clot initiation but potentiated 
maximum clot strength.  As AST is likely multifactorial in aetiology, in patients treated with bivalirudin, 
increased clot strength may contribute to this hazard in some individuals and this observation warrants 
further investigation. 
 
Keywords: bivalirudin; heparin; platelet function; thrombelastography; stent thrombosis; thrombin 
 
 
 
ACCEPTED MANUSCRIPT
 Downloaded for Vikram Khanna (vikram.khanna@nnuh.nhs.uk) at HE EofE - Norfolk and Norwich University Hospitals NHS Foundation Trust from ClinicalKey.com by Elsevier on
 October 22, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Khanna and Shahzad et al 
HEAT-PPCI Short TEG Platelet Substudy 
3 
 
Introduction   
In patients undergoing primary percutaneous coronary intervention (PPCI) for ST elevation myocardial 
infarction (STEMI), the risk of recurrent ischaemic events is important.  Despite pharmacological inhibition 
of periprocedural platelet function with conventional dual antiplatelet therapy (DAPT), platelets remain 
reactive to a multitude of other mediators, most notably thrombin, a potent platelet agonist and the final 
effector of the coagulation cascade.  Furthermore, recently concerns have been raised in STEMI patients 
with respect to the delayed onset of action of new oral P2Y12 inhibitors [1, 2] previously reported to have a 
more reliable and superior antiplatelet effect compared to clopidogrel [3, 4].  Consequently, adjunctive 
antithrombotic therapy remains an important component of treatment in patients undergoing PPCI.    
The optimal adjunctive antithrombotic regimen in PPCI remains contentious.  Historically, unfractionated 
heparin (UFH) has been the default anticoagulant administered during PCI.  Unlike heparin, bivalirudin has 
the theoretical advantage that it does not bind plasma proteins, is not neutralised by platelet factor 4, 
exerts its effector activity on thrombin directly without the need for co-factors and can bind thrombin in 
the fluid phase as well as circulating clot-bound thrombin [5].  However, despite its favourable profile, the 
net outcome benefits demonstrated in randomised controlled trials have been largely driven by reductions 
in bleeding complications rather than incremental benefits in reducing ischaemic events [6-10], and this 
has generally been when comparing it to a combination of heparin plus a glycoprotein IIb/IIIa inhibitor 
(GPI). 
Evolving trends in PPCI, including the use of potent P2Y12 inhibitors, transradial access and selective 
‘bailout’ use of GPI means that these trials no longer closely reflect contemporary practice.  The HEAT-PPCI 
trial was a randomised comparison of UFH and bivalirudin (with selective ‘bailout’ use of GPI in both arms) 
in patients undergoing PPCI and demonstrated a significant reduction in major adverse cardiovascular 
events in favour of UFH without excessive bleeding complications [11].  This benefit was largely driven by a 
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higher incidence of acute stent thrombosis (AST) in the bivalirudin arm, an observation consistent with 
previous trials [8, 10].  However, the mechanism of AST in bivalirudin-treated patients remains poorly 
understood.  Furthermore, data on the antiplatelet effects of bivalirudin are discrepant [12-15]. 
The primary objective of this prespecified HEAT-PPCI platelet substudy was to compare the antiplatelet 
and antithrombotic effects of bivalirudin and UFH in patients undergoing PPCI for STEMI using Short 
Thrombelastography (s-TEG), a whole blood platelet function assay, extensively validated in PCI 
populations [16-20].  
 
 
Methods 
Study Population and Design 
All patients in this platelet substudy were part of the HEAT-PPCI (How Effective are Antithrombotic 
Therapies in Primary Percutaneous Coronary Intervention Study) trial [11], a single centre, open label, 
randomised study comparing bivalirudin to UFH in a PPCI population.  The selection inclusion and exclusion 
criteria were as previously described in the HEAT-PPCI trial  [11].  Specifically, we enrolled adults (≥18 years 
age) presenting with STEMI activating the PPCI pathway, unless they had known intolerance, 
hypersensitivity, or contraindication to any trial drug; active bleeding at presentation; artificial ventilation, 
reduced conscious level or other factors precluding the administration of oral antiplatelet therapy; their 
physician refused to administer antiplatelet loading (uncertain diagnosis or risk of bleeding); or if they had 
previously been enrolled in the HEAT-PPCI trial. 
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Patients who received a GPI were additionally excluded from the present platelet substudy.  Due to logistic 
considerations patients were enrolled to this substudy only during the core operational hours of the 
research laboratory at Liverpool Heart and Chest Hospital.  
Platelet function testing with Multiple electrode aggregometry (MEA) at the end of the index procedure 
(EOP) was planned from inception of the trial to compare the differential effects of P2Y12 inhibitors on 
platelet reactivity and clinical events[21].   
In this paper, we present results from a ‘second phase’ of the platelet substudy designed specifically to 
compare the antiplatelet and antithrombotic effects of bivalirudin and heparin.  We elected to perform this 
comparison using s-TEG, a well-validated and versatile platelet function assay, given its unique ability to 
individually assess a variety of different agonist-specific pathways of clotting including adenosine 
diphosphate (ADP), arachidonic acid (AA) and thrombin-mediated clotting (TMC).  In this phase of the 
platelet substudy, all participants had blood samples taken at EOP, but also repeated at 24 hours.  
However, recruitment to this phase of the platelet substudy had to be deferred until a substantial 
amendment to the HEAT-PPCI study protocol relating to obtaining a second blood sample at 24 hours was 
approved by the Liverpool East, North West Research Ethics Committee.    
All patients received DAPT before PPCI as per routine practice at the host institution and its referring 
emergency departments.  Patients received the assigned study drug after entry to the catheter laboratory 
but before the angiographic findings were known.  UFH was given as a bolus dose of 70 U/kg bodyweight 
before the procedure.  Additional doses were administered if activated clotting time (ACT) values 5–15 min 
after the bolus dose or at EOP were less than 200s.  Bivalirudin was given as a bolus of 0.75 mg/kg followed 
by infusion of 1.75 mg/kg/hr for the duration of the procedure.  A rebolus of 0.3 mg/kg was administered if 
activated clotting time (ACT) values 5–15 min after the bolus dose or at the EOP were less than 225 s.  ACT 
was monitored with Actalyke XL MAX-ACT system (Helena Laboratories, Beaumont, TX, USA).   
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Blood Sampling and Sample Analysis 
Blood sampling 
Whole blood for platelet function testing was obtained via arterial sheath in the cardiac catheterisation lab 
at the EOP.  In patients assigned to receive bivalirudin, the infusion was still running at the time of 
sampling.  Blood sampling at the 24-hour time point was performed via venepuncture from the antecubital 
fossa.  The first 10ml (2 ml during venesection) were discarded and then blood was drawn into one 6 ml 
lithium heparin Vacutainer®, and one 2 ml Vacutainer® of 3.2% sodium citrate for TEG platelet mapping.  
The tubes were filled to capacity and inverted gently a few times to ensure proper mixing with the 
anticoagulant in situ.  According to manufacturer’s instructions, blood samples were incubated at room 
temperature for at least 15 min for TEG platelet mapping.  
 
TEG Platelet Mapping 
Briefly, the TEG® technology is based on a stationary pin on a torsion wire being suspended into an 
oscillating cup containing a small volume of whole blood at 37°C.  As clotting is stimulated with agonists, 
changes in its viscoelasticity are transmitted to the pin and the resulting torque generates an electrical 
signal producing a characteristic TEG® trace (Figure 1) [16].   
Samples were analysed using the modified TEG® platelet mapping system (Haemonetics Corp, MA, USA) as 
previously reported [16, 17].  Platelet agonists employed in the standard channels include: (i) Citrated 
blood activated by Kaolin (CK): kaolin stimulates clotting via the intrinsic coagulation pathway leading to 
thrombin generation and maximal platelet activation as thrombin is a potent platelet agonist, (ii) Activator 
F™ (Act F):  a mixture of reptilase and factor XIIIa, which generates fibrin clot without causing platelet 
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activation (iii) ADP: a combination of Activator F™ and ADP (2µM), (iv) AA: a combination of Activator F™ 
and AA (1mM).  In this platelet substudy we used an additional fifth channel (CKH) in which citrated whole 
blood was stimulated by kaolin in a cup coated with heparinase to neutralise the effects of heparin.  This 
channel provides a pure assessment of thrombin-mediated clotting (TMC) by eliminating the activity of any 
heparin that is present in the sample (endogenous or administered), thus providing an internal control for 
TMC in patients who had received heparin.  It therefore served as a control channel for comparison of the 
antithrombotic effects of bivalirudin and UFH.  Whole blood (340 µl of citrated blood for CK and CKH 
channel; 360 µl of heparinised blood for Act F, AA and ADP channels) was manually pipetted into the 
respective channels.  In blood preserved with the calcium chelating agent, citrate (i.e. CK and CKH channel), 
clotting was initiated by recalcification using 0.2M calcium chloride.   
The TEG® 5000 haemostasis analyser (Haemonetics Corp., Massachusetts, USA) and automated analytical 
software were used to measure the physical properties of clot formation to produce a characteristic TEG 
trace.  Observations were continued for at least 60 minutes.  Individual TEG traces were used to derive 
parameters relating to clot dynamics including R time, K time, α-angle, maximum amplitude (MA) and the 
Short Thrombelastography (s-TEG) parameter Area under the curve at 15 minutes (AUC15), as illustrated in 
Figure 1. 
 
Short Thrombelastography 
s-TEG is a novel modification of the TEG® platelet mapping assay, as previously described and validated 
[16, 17], which is based upon the concept of “Area under the curve at 15 minutes” (AUC15).  This 
incorporates both strength and speed of clot formation.  AUC15 is calculated using bespoke software 
(Areafinder 2:1) developed using National Instrument Labview 7.0.  AUC15 has been shown to correlate 
well with the conventional TEG® parameter maximum amplitude (MA) in assessment of responses to APT 
and is easily reproducible [17].   
ACCEPTED MANUSCRIPT
 Downloaded for Vikram Khanna (vikram.khanna@nnuh.nhs.uk) at HE EofE - Norfolk and Norwich University Hospitals NHS Foundation Trust from ClinicalKey.com by Elsevier on
 October 22, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Khanna and Shahzad et al 
HEAT-PPCI Short TEG Platelet Substudy 
8 
 
 
Statistical analysis 
Continuous variables are presented as mean ± 95% confidence interval (CI) of the mean for normally 
distributed data or median with interquartile range (IQR) if not.  Normality of data was tested using the 
Shapiro-Wilk test.  Non-normally distributed continuous data were compared using the Mann-Whitney U 
test.  Categorical variables are presented as frequencies (%).  A P value <0.05 was considered to represent 
statistical significance.  Statistical analyses were performed using SPSS version 21 (IBM Corp., Armonk, NY, 
USA).  
 
 
Results 
This TEG substudy includes 184 patients.  As outlined in the substudy flow chart (Figure 2), of the 1,812 
patients randomised in the HEAT-PPCI trial, 1,229 (67.8%) presented outside the core operating times of 
the research laboratory.  Four patients were deemed too unwell for blood sampling at EOP as the clinical 
team were occupied with patient resuscitation.  Specifically, 2 patients had multiple VF arrests requiring 
intubation and ventilation, one had left main stem dissection requiring emergency surgery and one patient 
had coronary perforation requiring emergency surgery.  Furthermore, 86 patients who received GPI were 
not included.  Finally, data from 15 bivalirudin-treated patients were excluded from this analysis as they 
exhibited a pattern of TMC consistent with heparin contamination.  Specifically, TMC was obliterated in the 
CK channel, consistent with the effects of heparin, but restored in the presence of heparinase (CKH 
channel), which neutralises heparin activity (as described above).  On careful review of source data there 
was definite evidence of only one patient having received fondaparinux and one patient receiving UFH 
prior to randomisation.  Platelet function data at the 24-hour time point for 21 patients (14 in the UFH arm 
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and 7 in the bivalirudin arm) bearing this characteristic pattern were also excluded from the analysis.   
Baseline characteristics in the substudy population (Table 1) were well matched between patients treated 
with bivalirudin (n = 92) and UFH (n = 92).   
 
Antiplatelet effects of heparin versus bivalirudin 
There were no significant differences in ADP- or AA-mediated platelet aggregation between the two groups 
at EOP or the 24-hour time point (Table 2).   
 
Antithrombotic effects of heparin versus bivalirudin 
End of procedure 
In the control channel (i.e. CKH channel in patients treated with UFH where TMC was evaluated in the 
presence of heparinase), the median and IQR for R time was 8.4 min [7.5 - 10], K time was 2.2 min [1.8 - 
2.7], α-angle was 59.8° [54.5 - 65.4], MA was 58.6 [55 - 63], and AUC15CKH was 965.7 [859.8 - 1090.4].  By 
contrast, in patients treated with UFH in the absence of heparinase (i.e. CK only), clotting in response to 
kaolin (i.e. TMC) at EOP was obliterated, at least for the duration of the observation period.  Consequently, 
no further TEG parameters relating to time to clot initiation (R time), maximum clot strength (i.e. MA), K-
time, α- angle or AUC15 (i.e. s-TEG) could be derived at this time point.   
Compared to control (i.e. CKH channel in patients treated with UFH) (n=90), bivalirudin (n = 91) 
significantly prolonged R time (19.7 min [15.9 – 25.4] vs. 8.4 min [7.5 - 10]; P < 0.0001), prolonged K-time 
(2.4 min [1.9 - 3.4] vs. 2.2 min [1.8 - 2.7]; P = 0.007) and increased MA (62.7 [58.6 - 67.4] vs. 58.6 [55 - 63]; 
P = 0.0005).  There were no significant differences in the α-angle (58.6° [47.3 - 64.1] vs. 59.8° [54.5 - 65.4]; 
P = 0.06) and AUC15CKH at EOP (1011.2 [808.6 - 1161] vs. 965.7 [859.8 - 1090.4], P = 0.72) between patients 
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treated with bivalirudin compared to control (Figure 3).   
 
24 hour time point 
At 24 hours, there were no significant differences in any TEG parameter (R time, K time, α angle, MA or 
AUC15) between patients treated with UFH and bivalirudin, regardless of whether heparinase was present 
(i.e. CKH) or not (i.e. CK only) (Figure 4).  
  
 
Discussion 
Two principal findings are reported in this study.  Firstly, s-TEG detected no significant differences in ADP- 
or AA-mediated platelet aggregation between UFH and bivalirudin at either time point (i.e. EOP or 24 
hours).  Secondly, UFH obliterated TMC, but, whilst bivalirudin prolonged time to clot initiation (R time) 
and propagation (K time), but was also associated with significantly greater maximum clot strength (i.e. 
MA) compared to control.   
Using flow cytometry, previous studies have compared the effects of bivalirudin and UFH on agonist-
mediated platelet activation, both ex vivo [13, 22] and in vitro [14, 23, 24].  Bivalirudin has been shown to 
have modest inhibitory effects on platelet activation although some authors have reported that it 
potentiates P-selectin surface expression [15].  By contrast, UFH has mostly been shown to potentiate 
platelet activation by initiating outside-in signalling via direct binding to αIIbβ3 integrin [25], though again 
there are discrepant data reported [26].  However, the overall significance of differential surface 
expression of platelet activation markers with these anticoagulant agents on agonist-mediated clotting and 
clinical outcome measures remains poorly understood.   
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A study in cardiac surgical patients demonstrated that both bivalirudin and UFH significantly attenuated 
ADP-mediated platelet aggregation, although the effects of bivalirudin were more pronounced [27].  By 
contrast, using MEA and light transmittance aggregometry (LTA), Sibbing et al demonstrated that in PCI 
patients preloaded with clopidogrel, whilst UFH had no significant effects, bivalirudin resulted in significant 
incremental inhibition of ADP-mediated aggregation [12].  Such antiaggregatory effects, albeit modest in 
magnitude, are significant and therefore, at least in theory, might be expected to mitigate the early hazard 
of periprocedural ischaemic events including AST.   However, despite this theoretical advantage, there are 
no consistent data from randomised trials supporting superiority of bivalirudin over UFH with respect to 
ischaemic end points.  On the contrary, bivalirudin has been consistently associated with an elevated risk 
of AST [8, 11, 28], at least in the absence of a prolonged post-PCI infusion [29], a finding which has led to 
downgrading of recommendations for bivalirudin to class IIa in the recent European guidelines [30]. 
In the present platelet substudy there were no significant differences in ADP- and AA-mediated platelet 
aggregation between UFH and bivalirudin at either time point (i.e. EOP or 24 hours).  Our findings are 
consistent with the DEACON study which also found no significant differences between UFH and bivalirudin 
in ADP-induced aggregation with LTA in patients undergoing PCI, regardless of whether they had been 
treated with GPI [31].  However, it is noteworthy that we found a trend towards significance in AA-
mediated aggregation between UFH and bivalirudin at 24 hours (p = 0.06).  Whilst it is conceivable that a 
larger sample size could potentially yield a statistically significant result, it is difficult to speculate a 
plausible mechanistic explanation for such a finding given that, with their short half lives, neither drug 
would be expected to have detectable activity at this time point.  Further studies adequately powered are 
required to confirm these findings.   
Whilst conventional assays for monitoring heparin-related blood clotting (e.g. ACT and activated partial 
thromboplastin time) terminate early after fibrin gel formation occurs in response to trace amounts of 
thrombin (< 5%), TEG continues profiling several aspects of clot dynamics on a temporal basis beyond the 
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initiation phase (i.e. clot propagation) which is typically characterised by a burst of thrombin generation (> 
95%).  TEG is therefore ideally suited for comprehensive characterisation of the effects of thrombin 
inhibitors on the viscoelastic properties of clot formation.  Indeed, several studies have already 
systematically evaluated a range of thrombin inhibitors with TEG, based on in vitro testing in healthy 
volunteers [32-36].  In accordance with our findings, these studies have shown that all thrombin inhibitors, 
including UFH and bivalirudin, prolong time to clot initiation (i.e. R time) and clot propagation (i.e. K time 
and α-angle) in a dose-dependent manner.  However, the effects of direct thrombin inhibitors (DTIs) in 
prolonging clot initiation and propagation are modest in comparison to those of UFH, which has the 
steepest concentration-response curve, again consistent with our findings.  In our study, UFH obliterated 
TMC at EOP, at least for the duration of the observation period.  These findings are also consistent with 
previous reports demonstrating that UFH not only inhibits clot initiation and propagation, but also 
significantly attenuates clot strength and rigidity in a concentration-dependent manner [32, 35, 36].   
To our knowledge, this study is the first to demonstrate that bivalirudin augments maximum clot strength. 
By contrast, the existing evidence is discrepant with respect to the reported effects of bivalirudin on the 
maximum tensile strength of a clot (i.e. MA).  Specifically, Young et al showed that clot rigidity and 
elasticity were relatively preserved even at high doses of bivalirudin, once kaolin-activated clotting finally 
commenced following a prolonged lag period [32].  By contrast, Taketomi et al showed that at therapeutic 
concentrations (similar to those employed in PCI) bivalirudin resulted in modest increases in MA in 
response to direct stimulation with thrombin, when compared to control, though this was not statistically 
significant in their study [34].  It is noteworthy that we evaluated the pharmacodynamic effects of these 
anticoagulants ex vivo in a real-world population of STEMI patients undergoing PPCI, which likely 
represents a more prothrombotic state than that prevalent in blood from healthy volunteers tested in 
vitro. 
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The differences between UFH and bivalirudin reported in this study are consistent with their known 
pharmacological properties.  Specifically, heparin-mediated binding of antithrombin leads to the formation 
of a ternary complex and irreversible conformational changes to the active site of thrombin.  By contrast, 
bivalirudin comprises a peptide directed against the thrombin active site linked via a tetraglycine spacer to 
a synthetic dodecapeptide analogue of the C-terminus of hirudin [37] that binds to exosite 1 on thrombin 
(i.e. the binding site for fibrinogen and thrombomodulin).  Once bound in a bivalent fashion (i.e. to the 
active site and exosite 1), thrombin is rendered inactive only transiently.  Circulating proteases including 
thrombin itself cleave bivalirudin close to the N-terminus liberating the amino-terminal moiety from the 
active site, thereby allowing resumption of thrombin’s catalytic activities [38].  Its relatively short plasma 
half life (~ 25 minutes) has therefore been cited as a plausible explanation for the higher incidence of AST 
associated with bivalirudin.  Undoubtedly, this mechanistic explanation has greater biological relevance 
given that there is now also convincing evidence for a delayed onset of action of P2Y12 inhibitors in STEMI 
[1, 39].   Consequently, this has prompted analyses of prolonged post-PCI infusions of bivalirudin as a 
strategy to mitigate the higher incidence of AST, which has shown encouraging results [29, 40]. 
Nevertheless, numerous studies have also reported that at low concentrations, bivalirudin [35, 36, 41] and 
other DTIs [42, 43], produce a paradoxical increase in tissue factor (TF)-triggered thrombin generation (TG) 
in vitro.  This exaggerated TG at low concentrations of DTIs has been attributed to the suppression of the 
thrombin-thrombomodulin (TM)-induced negative-feedback inhibition of thrombin via protein C [42, 43],  
which when activated naturally exerts a potent anticoagulant effect via proteolysis of factor (F) Va and 
FVIIIa.  Following proteolytic cleavage, the carboxyl-terminal remnant of bivalirudin transforms into a 
competitive inhibitor of exosite 1 substrates including fibrinogen and TM [38], thus potentially exerting an 
ongoing inhibitory effect on thrombin-TM mediated activation of protein C.   
A mechanism of rebound clotting activation could potentially explain the increase in clot strength noted at 
EOP in this study.  Nevertheless, the increase in clot strength, whilst statically significant is modest and 
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based on existing evidence is unlikely to independently account for the higher incidence of AST observed in 
patients treated with bivalirudin.  However, the pathophysiology of stent thrombosis, which remains 
poorly understood, is multifactorial and a variety of factors including patient comorbidities, stent design, 
lesion morphology, high platelet reactivity and procedural factors including stent underexpansion and 
malaposition have been implicated in its aetiology.  It is therefore conceivable that increased maximum 
clot strength reported here in bivalirudin-treated patients could contribute to triggering AST in some 
individuals. Further studies to elucidate the precise mechanism and clinical significance of this observed 
increase in clot strength in patients treated with bivalirudin are warranted. 
This substudy has several limitations.  Firstly, we have assumed that baseline platelet reactivity prior to 
drug administration was similar in both treatment groups, though this was not formally confirmed.  
Secondly, we were unable to compare the effects of these antithrombotic regimens at therapeutic doses 
on TG as this was neither measured directly nor assayed via surrogate markers.  Finally, we have not 
examined the validity of using the CKH channel in patients treated with UFH as a control group for 
comparison against patients treated with bivalirudin, although our previous clinical data strongly supports 
this assumption.   
In conclusion, whilst there were no significant differences between UFH and bivalirudin with respect to 
their effects on platelet aggregation in response to ADP or AA, we did observe important differences in the 
viscoelastic properties of clot formation in response to thrombin stimulation.  Specifically, whilst heparin 
obliterated TMC, bivalirudin prolonged clot initiation and propagation, but was also associated with a 
significant increase in maximum clot strength.  This effect could be one factor that contributes to AST in 
susceptible individuals and warrants further investigation.     
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Legends 
Figure 1. Typical TEG trace illustrating the parameters: (i) R time  - latent period from start of sample 
analysis to clot initiation); (ii) K time - time taken to attain a fixed viscoelasticity (i.e. amplitude of 20 mm) 
which is a measure of clot kinetics; (iii) α-angle - gradient formed by angle of initial trace which represents 
the rapidity of fibrin build-up and cross-linking in the forming clot; (iv) maximum clot strength (MA) – is the 
final strength of the clot; (v) AUC15 – is the Area under the curve at 15 minutes (AUC15) which reports on 
both the speed of clot formation as well as clot strength (shaded area). 
 
Figure 2.  Study flow chart. 
 
Figure 3.  Comparison of Thrombelastography-derived indices between patients treated with 
unfractionated heparin and bivalirudin at end of procedure when citrated whole blood was stimulated with 
kaolin (thrombin-mediated clotting) in the presence (CKH channel) and absence of heparinase (CK 
channel): (A) R time; (B) K time; (C) α-angle; (D); maximum amplitude (MA) and (E) area under the curve at 
15 minutes (AUC15).  
 
Figure 4. Comparison of Thrombelastography-derived indices between patients treated with 
unfractionated heparin and bivalirudin at 24 hours when citrated whole blood was stimulated with kaolin 
(thrombin-mediated clotting) in the presence (CKH channel) and absence of heparinase (CK channel): (A) R 
time; (B) K time; (C) α-angle; (D); maximum amplitude (MA) and (E) area under the curve at 15 minutes 
(AUC15). 
 
Table 1.  Summary of baseline characteristics, laboratory investigations and drug use. 
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Table 2.  Comparison of ADP and AA-mediated platelet aggregation in patients treated with unfractionated 
heparin to those treated with bivalirudin at the end of the PCI procedure and 24-hour time point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
 Downloaded for Vikram Khanna (vikram.khanna@nnuh.nhs.uk) at HE EofE - Norfolk and Norwich University Hospitals NHS Foundation Trust from ClinicalKey.com by Elsevier on
 October 22, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Khanna and Shahzad et al 
HEAT-PPCI Short TEG Platelet Substudy 
18 
 
Figures 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
 Downloaded for Vikram Khanna (vikram.khanna@nnuh.nhs.uk) at HE EofE - Norfolk and Norwich University Hospitals NHS Foundation Trust from ClinicalKey.com by Elsevier on
 October 22, 2018. For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Khanna and Shahzad et al 
HEAT-PPCI Short TEG Platelet Substudy 
19 
 
Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
583 recruited during working hours of research laboratory 
558 had platelet function testing at EOP 
1,812 patients randomised in HEAT-PPCI Study 
1,229 recruited outside working hours of research 
laboratory 
86 received GP IIb/IIIa inhibitors 
15 suspected of Sample contamination with heparin 
 
        
 457 had evaluable platelet function data at EOP 
245 before Phase 2 of substudy commenced 
28 equipment or staff unavailable / sample error 
 
        
 184 evaluable s-TEG data at EOP 
92 received heparin 
 
92 received bivalirudin 
 
25 no platelet function testing at end of procedure (EOP) 
        8 equipment unavailable 
        2 died during procedure 
        4 too unwell to have sample taken 
        11 blood sample not taken by the operator 
21 suspected of sample contamination with heparin  
8 equipment unavailable / sample error 
6 patients unwell / death / stay less than 24 hours 
2 reason unknown  
 
        
 147 evaluable s-TEG data at 24 hours 
72 received heparin 
 
75 received bivalirudin 
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Figure 3. 
            
 
    C                                                                             D                                                                              E     
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Figure 4.   
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Tables 
Table 1. 
  
Bivalirudin                  
(n = 92) 
 Heparin                    
(n = 92) 
Age, years  65.7 ± 2.6 63 ± 2.7 
Sex, female 32/92 (34.8%) 26/92 (28.3%) 
Bodyweight, kg     
             Data available 74 (80.4%) 82 (89.1%) 
             Mean ± 95% CI of mean 78.9 ± 3.8 79.1 ± 3.0 
Ethnicity, White 85/88 (96.6%) 84/89 (94.4%) 
Comorbidities     
Hypertension 36/92 (38.5%) 37/91 (40.7%) 
Hyperlipidaemia 29/89 (32.6%) 35/92 (38.0%) 
Diabetes Mellitus 12/92 (13.0%) 12/91 (13.2%) 
Family history of CVD 40/90 (44.4%) 42/89 (47.2%) 
Current Smoker 34/91 (37.4%) 37/89 (41.6%) 
Previous myocardial infarction 10/92 (10.9%) 10/92 (10.9%) 
Previous PCI 5/92 (5.4%) 6/91 (6.6%) 
Previous CABG 3/92 (3.3%) 3/92 (3.3%) 
Platelet count      
Data available 89 (96.7%) 91 (98.9%) 
Median [IQR] 233 [190 – 282] 222 [186.5 - 263] 
Estimated GFR     
Data available 90 (97.8%) 92 (100%) 
Median [IQR] 75.5 [60 - 90] 77 [62.5 - 90] 
Haemoglobin      
Data available 91 (98.9%) 92 (100%) 
Median [IQR] 13.5 [12.1 - 14.6] 13.7 [12.6 -14.8] 
P2Y12 inhibitor     
Clopidogrel 6/92 (6.5%) 5/92 (5.4%) 
Prasugrel 1/92 (1.1%) 1/92 (1.1%) 
Ticagrelor 85/92 (92.4%) 84/92 (91.3%) 
None 0/92  2/92 (2.2%) 
Other anticoagulation   
Warfarin 5/92 (5.4%) 4/92 (4.3%) 
Fondaparinux 2/92 (2.2%) 6/92 (6.5%) 
Low-molecular weight heparin 1/92  0 
Other 1/92 0 
Time between LD and EOP sampling (minutes)   
Aspirin     
Data available 91 (98.9%) 85 (92.4%) 
Median [IQR] 95 [79 – 117.5] 94 [75 - 110] 
P2Y12 inhibitor     
Data available 90 (97.8%) 85 (92.4%) 
Median [IQR] 67 [44 – 102] 55 [40 - 85] 
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Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
End of Procedure 
P 
value 
24 hours 
P 
value 
UFH Bivalirudin UFH Bivalirudin 
N 
Median                 
[IQR] N 
Median 
[IQR] N 
Median 
[IQR] N 
Median 
[IQR] 
s-TEG 
AUC15AA 91 
457.3                 
[225.9 - 648.5] 
92 
379.4                        
[251.6 – 573.3] 
0.60 68 
150.1                    
[104.7 - 318.7] 
73 
227.6                              
[142.7 – 298.8] 
0.06 
AUC15ADP 91 
460.8                   
[195.2 - 732.9] 
92 
537.4                    
[303.1 – 890.2] 
0.08 70 
140                              
[77.1 - 309.9] 
74 
186.5         
[119.2 – 301.5] 
0.09 
s-TEG, Short Thrombelastography; IQR, Interquartile range; UFH, unfractionated heparin 
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Highlights 
 Comparing the antiplatelet and antithrombotic effects of bivalirudin and heparin 
 No significant differences in the antiplatelet effects of bivalirudin and heparin    
 Heparin totally obliterated thrombin-mediated clotting 
 Bivalirudin prolonged clot initiation/propagation and increased clot strength   
 Increased clot strength with bivalirudin may contribute to acute stent thrombosis 
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